Priority 9 Sight Loss and Vision PSP Childhood Disorder
| UNCERTAINTY: Can better treatments for glaucoma in children be developed? (JLA PSP Priority 9) | |
|---|---|
| Overall ranking | 9 |
| JLA question ID | 0014c/9 |
| Explanatory note | No relevant systematic reviews identified at the time of the PSP |
| Evidence |
None identified |
| Health Research Classification System category | Eye |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | None provided |
| Systematic reviews that need updating or extending | None identified |
| Ongoing controlled trials |
A study of the safety and efficacy of bimatoprost ophthalmic solution in paediatric patients with glaucoma NCT01426113 Study of travoprost ophthalmic solution, 0.004% compared to timolol (0.5% or 0.25%) in pediatric glaucoma patients NCT01652664 A 3 month, multicenter, double-masked safety and efficacy study of travoprost ophthalmic solution, 0.004% compared to timolol (0.5% or 0.25%) in pediatric glaucoma patients - travoprost 0.004% in pediatric glaucoma patients https://www.clinicaltrialsregister.eu/ctr-search/search? query=eudract_number:2012-001324-34 |
| Submitted by | Patients |
| Outcomes to be measured | Management and or change of symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs |
| PSP information | |
|---|---|
| PSP unique ID | 0014c |
| PSP name | Sight Loss and Vision - Childhood Onset Eye Disorders |
| Total number of uncertainties identified by this PSP. | 69 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | April and May 2013 |